A Phase I/II Trial of Gemtuzumab Ozogamicin in Combination with Cytarabine and Anthracyclines(Daunorubicin or Idarubicin) for CD33-Positive Refractory or Relapsed AML Patients Younger Than65Years. Results of Phase I Parts of the JALSG-AML206Study
A Phase I/II Trial of Gemtuzumab Ozogamicin in Combination with Cytarabine and Anthracyclines(Daunorubicin or Idarubicin) for CD33-Positive Refractory or Relapsed AML Patients Younger Than65Years. Results of Phase I Parts of the JALSG-AML206Study
复制标题
Gemtuzumab Ozogamicin 联合阿糖胞苷和蒽环类药物（柔红霉素或伊达比星）治疗 65 岁以下 CD33 阳性难治性或复发性 AML 患者的 I/II 期试验。
DOI：
--
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Ohnishi K
中科院分区：
文献类型：
--
作者：
Usui N;Takeshita A;Nakaseko C;Dobashi N;Fujita H;Kiyoi H;Kobayashi Y;Fujisawa S;Yagasaki F;Nishii K;Kiguchi T;Miyazaki Y;Ohtake S;Miyawaki S;Ohno R;Naoe T;Ohnishi K
